- Published on
Toxicology – Calcium Channel Blocker Toxicity
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
- Mental status may initially remain normal despite significant cardiovascular compromise.
- Hyperglycemia helps differentiate CCB toxicity from beta-blocker overdose.
- ECG findings may include PR prolongation, sinus arrest, or high-grade heart block.
- Atropine may be attempted for bradycardia but is often ineffective.
0 Comments
